Merck will spend $8.4 billion to buy Cubist Pharmaceuticals and push deeper into treating so-called "superbugs" that have drawn dire warnings from global health organizations. The company said Monday that the deal will give it stronger footing in hospital acute care and help it address antibiotic resistance, which the Whitehouse Station, New Jersey, drugmaker called a critical area of unmet medical need.